Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
But Phase III Is Already Enrolled
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
